JP2017526677A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017526677A5 JP2017526677A5 JP2017511226A JP2017511226A JP2017526677A5 JP 2017526677 A5 JP2017526677 A5 JP 2017526677A5 JP 2017511226 A JP2017511226 A JP 2017511226A JP 2017511226 A JP2017511226 A JP 2017511226A JP 2017526677 A5 JP2017526677 A5 JP 2017526677A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- pharmaceutically acceptable
- solvate
- acceptable salt
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 34
- 125000000217 alkyl group Chemical group 0.000 claims description 24
- 150000003839 salts Chemical class 0.000 claims description 19
- 239000012453 solvate Substances 0.000 claims description 19
- 229910052799 carbon Inorganic materials 0.000 claims description 16
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 16
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 16
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 12
- 206010028980 Neoplasm Diseases 0.000 claims description 10
- 201000011510 cancer Diseases 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 8
- 125000001475 halogen functional group Chemical group 0.000 claims description 8
- -1 C 1 -C 6 alkyl Chemical group 0.000 claims description 7
- 125000001041 indolyl group Chemical group 0.000 claims description 6
- 125000001624 naphthyl group Chemical group 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical compound [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 claims description 6
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims description 4
- 239000002246 antineoplastic agent Substances 0.000 claims description 4
- 229940127089 cytotoxic agent Drugs 0.000 claims description 4
- 125000004076 pyridyl group Chemical group 0.000 claims description 4
- 229940124597 therapeutic agent Drugs 0.000 claims description 4
- 125000004432 carbon atom Chemical group C* 0.000 claims description 3
- 125000002993 cycloalkylene group Chemical group 0.000 claims description 3
- 201000007270 liver cancer Diseases 0.000 claims description 3
- 208000014018 liver neoplasm Diseases 0.000 claims description 3
- 125000004916 (C1-C6) alkylcarbonyl group Chemical group 0.000 claims description 2
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 claims description 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 2
- 125000006176 2-ethylbutyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])*)C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 claims description 2
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 2
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
- 230000036457 multidrug resistance Effects 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000003607 modifier Substances 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 125000006254 cycloalkyl carbonyl group Chemical group 0.000 description 1
- 239000000367 immunologic factor Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020023051A JP6905609B2 (ja) | 2014-08-25 | 2020-02-14 | 癌の処置のためのウリジンのジオキソラン類似体 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE1450983-0 | 2014-08-25 | ||
| SE1450983 | 2014-08-25 | ||
| SE1550858 | 2015-06-22 | ||
| SE1550858-3 | 2015-06-22 | ||
| PCT/EP2015/069370 WO2016030335A1 (en) | 2014-08-25 | 2015-08-24 | Dioxolane analogues of uridine for the treatment of cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020023051A Division JP6905609B2 (ja) | 2014-08-25 | 2020-02-14 | 癌の処置のためのウリジンのジオキソラン類似体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017526677A JP2017526677A (ja) | 2017-09-14 |
| JP2017526677A5 true JP2017526677A5 (enExample) | 2018-09-27 |
| JP6663424B2 JP6663424B2 (ja) | 2020-03-11 |
Family
ID=54014804
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017511226A Active JP6663424B2 (ja) | 2014-08-25 | 2015-08-24 | 癌の処置のためのウリジンのジオキソラン類似体 |
| JP2020023051A Active JP6905609B2 (ja) | 2014-08-25 | 2020-02-14 | 癌の処置のためのウリジンのジオキソラン類似体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020023051A Active JP6905609B2 (ja) | 2014-08-25 | 2020-02-14 | 癌の処置のためのウリジンのジオキソラン類似体 |
Country Status (24)
| Country | Link |
|---|---|
| US (7) | US10144750B2 (enExample) |
| EP (2) | EP3186244B1 (enExample) |
| JP (2) | JP6663424B2 (enExample) |
| KR (2) | KR102396905B1 (enExample) |
| CN (4) | CN107074826B (enExample) |
| AU (2) | AU2015308988C1 (enExample) |
| BR (1) | BR112017003898B1 (enExample) |
| CA (2) | CA2956251C (enExample) |
| CY (1) | CY1122945T1 (enExample) |
| DK (2) | DK3572410T3 (enExample) |
| EA (2) | EA031106B1 (enExample) |
| ES (2) | ES2927212T3 (enExample) |
| HR (1) | HRP20201023T1 (enExample) |
| HU (2) | HUE059640T2 (enExample) |
| IL (2) | IL250344B (enExample) |
| MX (1) | MX369649B (enExample) |
| MY (2) | MY188089A (enExample) |
| NZ (2) | NZ762628A (enExample) |
| PH (2) | PH12017500184B1 (enExample) |
| PL (2) | PL3186244T3 (enExample) |
| PT (2) | PT3572410T (enExample) |
| SG (3) | SG11201701172SA (enExample) |
| WO (1) | WO2016030335A1 (enExample) |
| ZA (1) | ZA201802864B (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT3572410T (pt) | 2014-08-25 | 2022-09-15 | Medivir Ab | Análogos dioxolano de uridina para o tratamento de cancro |
| CN106543220A (zh) * | 2015-09-16 | 2017-03-29 | 博瑞生物医药（苏州）股份有限公司 | 氨基磷酸酯化合物及其制备方法和晶体 |
| MX386478B (es) * | 2015-12-11 | 2025-03-18 | Laurus Labs Ltd | Sintesis diaestereoselectiva de derivados de fosfato y del profarmaco de gemcitabina nuc-1031. |
| CN109069509B (zh) * | 2016-03-02 | 2020-10-16 | 麦迪维尔股份公司 | 索拉非尼或瑞戈非尼与曲沙他滨的氨基磷酸酯前药的组合治疗 |
| CN106432328B (zh) * | 2016-09-14 | 2019-03-22 | 江苏福瑞生物医药有限公司 | 一种索非布韦中间体的制备方法 |
| EP3541824A1 (en) * | 2016-11-18 | 2019-09-25 | Neurovive Pharmaceutical AB | Liver prodrugs of mitochondrial proton ionophores |
| GB201709471D0 (en) * | 2017-06-14 | 2017-07-26 | Nucana Biomed Ltd | Diastereoselective synthesis of hosphate derivatives |
| WO2019245444A1 (en) | 2018-06-21 | 2019-12-26 | Medivir Ab | Base-modified cytidine nucleotides for leukemia therapy |
| JP7337539B2 (ja) * | 2018-06-21 | 2023-09-04 | メディヴィル・アクチエボラーグ | 白血病療法のための塩基修飾シチジンヌクレオチド |
| CN113453685A (zh) * | 2019-02-18 | 2021-09-28 | 美迪维尔公司 | 使用口服给药的二氧戊环核苷酸与抗pd1或抗pdl1单克隆抗体的组合治疗肝癌的方法 |
| CN110964057B (zh) * | 2019-12-25 | 2022-05-06 | 东南大学 | 一种利用微流体反应装置制备索非布韦中间体的方法 |
| CN113402546A (zh) * | 2020-03-17 | 2021-09-17 | 浙江四维医药科技有限公司 | 一种瑞德西韦磷酸中间体尾链动态动力学拆分方法 |
| TW202200140A (zh) * | 2020-04-15 | 2022-01-01 | 瑞典商米迪維艾克提伯拉公司 | 用於肝癌之miv-818/樂伐替尼(lenvatinib)組合療法 |
| CN113754692B (zh) * | 2020-06-03 | 2022-06-10 | 上海交通大学 | 瑞德西韦中间体(s,s)-氨基磷酸酯的不对称催化合成方法 |
| CN114685558A (zh) * | 2020-12-28 | 2022-07-01 | 尚科生物医药（上海）有限公司 | 一种瑞德西韦中间体的制备方法 |
| CN114249764A (zh) * | 2021-11-10 | 2022-03-29 | 宁波大学 | 一种磷酰胺酯类前药的中间体及其制备方法与应用 |
| WO2025155547A1 (en) * | 2024-01-17 | 2025-07-24 | University Of Georgia Research Foundation, Inc. | An efficient synthesis of beta-l-5-[(e)-2-bromovinyl)-1-((2s,4s)-2-(hydroxymethyl)-1,3-(dioxolane-4-yl) uracil)] (l-bhdu) via chiral pure l-dioxolane |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5444063A (en) * | 1990-12-05 | 1995-08-22 | Emory University | Enantiomerically pure β-D-dioxolane nucleosides with selective anti-Hepatitis B virus activity |
| US6022876A (en) | 1996-11-15 | 2000-02-08 | Yale University | L-β-dioxolane uridine analogs and methods for treating and preventing Epstein-Barr virus infections |
| CA2425359A1 (en) * | 2000-10-13 | 2002-04-18 | Shire Biochem Inc. | Dioxolane analogs for improved inter-cellular delivery |
| GB0317009D0 (en) * | 2003-07-21 | 2003-08-27 | Univ Cardiff | Chemical compounds |
| WO2007106450A2 (en) * | 2006-03-10 | 2007-09-20 | University Of Georgia Research Foundation, Inc. | Diketo acids with nucleobase scaffolds: anti-hiv replication inhibitors targeted at hiv integrase in combination therapy |
| CA2662147A1 (en) | 2006-09-01 | 2008-03-13 | University Of Georgia Research Foundation, Inc. | L-oddc prodrugs for cancer |
| PL216525B1 (pl) * | 2006-10-17 | 2014-04-30 | Ct Badań Molekularnych I Makromolekularnych Polskiej Akademii Nauk | 5'-O-[(N-acylo)amidoditiofosforano] nukleozydy oraz sposób wytwarzania 5'-O-[(N-acylo)amidofosforano]-,5'-O-[(N-acylo)amidotiofosforano]-, 5'-O-[(N-acylo)amidoditiofosforano]nukleozydów |
| US20130143835A1 (en) * | 2011-12-05 | 2013-06-06 | Medivir Ab | HCV Polymerase Inhibitors |
| AU2014354775A1 (en) * | 2013-11-27 | 2016-05-19 | Idenix Pharmaceuticals Llc | Nucleotides for the treatment of liver cancer |
| PT3572410T (pt) * | 2014-08-25 | 2022-09-15 | Medivir Ab | Análogos dioxolano de uridina para o tratamento de cancro |
-
2015
- 2015-08-24 PT PT191778240T patent/PT3572410T/pt unknown
- 2015-08-24 PL PL15756888T patent/PL3186244T3/pl unknown
- 2015-08-24 CA CA2956251A patent/CA2956251C/en active Active
- 2015-08-24 SG SG11201701172SA patent/SG11201701172SA/en unknown
- 2015-08-24 PT PT157568882T patent/PT3186244T/pt unknown
- 2015-08-24 EA EA201790328A patent/EA031106B1/ru not_active IP Right Cessation
- 2015-08-24 HU HUE19177824A patent/HUE059640T2/hu unknown
- 2015-08-24 US US15/506,692 patent/US10144750B2/en active Active
- 2015-08-24 ES ES19177824T patent/ES2927212T3/es active Active
- 2015-08-24 SG SG10202001117YA patent/SG10202001117YA/en unknown
- 2015-08-24 CN CN201580056640.7A patent/CN107074826B/zh active Active
- 2015-08-24 JP JP2017511226A patent/JP6663424B2/ja active Active
- 2015-08-24 KR KR1020177008235A patent/KR102396905B1/ko active Active
- 2015-08-24 DK DK19177824.0T patent/DK3572410T3/da active
- 2015-08-24 MY MYPI2017700615A patent/MY188089A/en unknown
- 2015-08-24 EA EA201890648A patent/EA033300B1/ru not_active IP Right Cessation
- 2015-08-24 SG SG10201911558UA patent/SG10201911558UA/en unknown
- 2015-08-24 HU HUE15756888A patent/HUE050705T2/hu unknown
- 2015-08-24 NZ NZ762628A patent/NZ762628A/en unknown
- 2015-08-24 NZ NZ729118A patent/NZ729118A/en unknown
- 2015-08-24 WO PCT/EP2015/069370 patent/WO2016030335A1/en not_active Ceased
- 2015-08-24 PL PL19177824.0T patent/PL3572410T3/pl unknown
- 2015-08-24 KR KR1020207008682A patent/KR102398714B1/ko active Active
- 2015-08-24 EP EP15756888.2A patent/EP3186244B1/en active Active
- 2015-08-24 CN CN202010199579.4A patent/CN111269264A/zh active Pending
- 2015-08-24 MX MX2017002328A patent/MX369649B/es active IP Right Grant
- 2015-08-24 ES ES15756888T patent/ES2796089T3/es active Active
- 2015-08-24 HR HRP20201023TT patent/HRP20201023T1/hr unknown
- 2015-08-24 CA CA3128645A patent/CA3128645C/en active Active
- 2015-08-24 DK DK15756888.2T patent/DK3186244T3/da active
- 2015-08-24 CN CN201911149251.5A patent/CN110804072B/zh active Active
- 2015-08-24 EP EP19177824.0A patent/EP3572410B1/en active Active
- 2015-08-24 AU AU2015308988A patent/AU2015308988C1/en active Active
- 2015-08-24 CN CN201911148331.9A patent/CN110790789B/zh active Active
- 2015-08-24 BR BR112017003898-6A patent/BR112017003898B1/pt active IP Right Grant
-
2017
- 2017-01-30 IL IL250344A patent/IL250344B/en active IP Right Grant
- 2017-01-31 PH PH12017500184A patent/PH12017500184B1/en unknown
- 2017-02-22 MY MYPI2021007010A patent/MY198325A/en unknown
-
2018
- 2018-03-20 AU AU2018201980A patent/AU2018201980B2/en active Active
- 2018-05-02 ZA ZA2018/02864A patent/ZA201802864B/en unknown
- 2018-12-03 US US16/208,083 patent/US10336780B2/en active Active
-
2019
- 2019-05-21 IL IL266766A patent/IL266766B/en active IP Right Grant
- 2019-07-01 US US16/459,165 patent/US10654877B2/en active Active
- 2019-08-19 PH PH12019501919A patent/PH12019501919A1/en unknown
-
2020
- 2020-02-14 JP JP2020023051A patent/JP6905609B2/ja active Active
- 2020-04-13 US US16/847,477 patent/US10822360B2/en active Active
- 2020-05-22 CY CY20201100469T patent/CY1122945T1/el unknown
- 2020-11-02 US US17/087,483 patent/US11447511B2/en active Active
-
2022
- 2022-09-19 US US17/948,050 patent/US20230117570A1/en not_active Abandoned
-
2023
- 2023-05-31 US US18/326,992 patent/US20230382931A1/en not_active Abandoned